Meta-Analysis of Monotherapy Versus Combination Therapy for Pulmonary Arterial HypertensionFOX, Benjamin D; SHIMONY, Avi; LANGLEBEN, David et al.The American journal of cardiology. 2011, Vol 108, Num 8, pp 1177-1182, issn 0002-9149, 6 p.Article

Pulmonary arterial hypertension: Pathophysiology and anesthetic approachBLAISE, Gilbert; LANGLEBEN, David; HUBEH, Bernard et al.Anesthesiology (Philadelphia). 2003, Vol 99, Num 6, pp 1415-1432, issn 0003-3022, 18 p.Article

The endothelin system in pulmonary hypertensionMICHEL, René P; LANGLEBEN, David; DUPUIS, Jocelyn et al.Canadian journal of physiology and pharmacology. 2003, Vol 81, Num 6, pp 542-554, issn 0008-4212, 13 p.Article

Riociguat for the Treatment of Pulmonary Arterial HypertensionGHOFRANI, Hossein-Ardeschir; GALIE, Nazzareno; NEUSER, Dieter et al.The New England journal of medicine. 2013, Vol 369, Num 4, pp 330-340, issn 0028-4793, 11 p.Article

Etiology-specific endothelin-1 clearance in human precapillary pulmonary hypertensionLANGLEBEN, David; DUPUIS, Jocelyn; LANGLEBEN, Isaac et al.Chest. 2006, Vol 129, Num 3, pp 689-695, issn 0012-3692, 7 p.Article

Pulmonary capillary endothelial dysfunction in early systemic sclerosisORFANOS, Stylianos E; PSEVDI, Ekaterini; STRATIGIS, Nikolas et al.Arthritis and rheumatism. 2001, Vol 44, Num 4, pp 902-911, issn 0004-3591Article

Treatment of pulmonary arterial hypertension with the selective endothelin-a receptor antagonist sitaxsentanBARST, Robyn J; LANGLEBEN, David; BADESCH, David et al.Journal of the American College of Cardiology. 2006, Vol 47, Num 10, pp 2049-2056, issn 0735-1097, 8 p.Article

Sitaxsentan therapy for pulmonary arterial hypertensionBARST, Robyn J; LANGLEBEN, David; ZWICKE, Diane et al.American journal of respiratory and critical care medicine. 2004, Vol 169, Num 4, pp 441-447, issn 1073-449X, 7 p.Article

Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in acute lung injuryORFANOS, Stylianos E; ARMAGANIDIS, Apostolos; GLYNOS, Constantinos et al.Circulation (New York, N.Y.). 2000, Vol 102, Num 16, pp 2011-2018, issn 0009-7322Article

Updated Clinical Classification of Pulmonary HypertensionSIMONNEAU, Gérald; ROBBINS, Ivan M; KROWKA, Michael J et al.Journal of the American College of Cardiology. 2009, Vol 54, Num 1, issn 0735-1097, S43-S54, SUPArticle

Pulmonary Capillary Endothelial Metabolic Dysfunction : Severity in Pulmonary Arterial Hypertension Related to Connective Tissue Disease Versus Idiopathic Pulmonary Arterial HypertensionLANGLEBEN, David; ORFANOS, Stylianos E; GIOVINAZZO, Michele et al.Arthritis and rheumatism. 2008, Vol 58, Num 4, pp 1156-1164, issn 0004-3591, 9 p.Article

Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-a receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: A 1-year follow-up studyLANGLEBEN, David; HIRSCH, Andrew M; SHALIT, Eileen et al.Chest. 2004, Vol 126, Num 4, pp 1377-1381, issn 0012-3692, 5 p.Article

Clinical classification of Pulmonary HypertensionSIMONNEAU, Gerald; GALIE, Nazzareno; RICH, Stuart et al.Journal of the American College of Cardiology. 2004, Vol 43, Num 12, pp 5S-12S, issn 0735-1097, SUPConference Paper

High prevalence of occult left heart disease in scleroderma-pulmonary hypertensionFOX, Benjamin D; SHIMONY, Avi; SERBAN, Alexandrina et al.The European respiratory journal. 2013, Vol 42, Num 4, pp 1083-1091, issn 0903-1936, 9 p.Article

Definitions and Diagnosis of Pulmonary HypertensionHOEPER, Marius M; BOGAARD, Harm Jan; WILKINS, Martin R et al.Journal of the American College of Cardiology. 2013, Vol 62, Num 25, issn 0735-1097, D42-D50, SUPDConference Paper

Temporal trends and drug exposures in pulmonary hypertension : An American experienceWALKER, Alexander M; LANGLEBEN, David; BOURGE, Robert C et al.The American heart journal. 2006, Vol 152, Num 3, pp 521-526, issn 0002-8703, 6 p.Article

Matrix metalloproteinases in the urine of patients with pulmonary arterial hypertensionBENISTY, Jacques I; FOLKMAN, Judah; ZURAKOWSKI, David et al.Chest. 2005, Vol 128, Num 6, issn 0012-3692, p. 572S, SUPConference Paper

Altitude-related hypoxia: Risk assessment and management for passengers on commerical aircraftMORTAZAVI, Amir; EISENBERG, Mark J; LANGLEBEN, David et al.Aviation, space, and environmental medicine. 2003, Vol 74, Num 9, pp 922-927, issn 0095-6562, 6 p.Article

Prevalence and Impact of Coronary Artery Disease in Patients With Pulmonary Arterial HypertensionSHIMONY, Avi; EISENBERG, Mark Jeffrey; LANGLEBEN, David et al.The American journal of cardiology. 2011, Vol 108, Num 3, pp 460-464, issn 0002-9149, 5 p.Article

Depressive symptoms in relation to physical functioning in pulmonary hypertensionLOOPER, Karl J; PIERRE, Andrena; DUNKLEY, David M et al.Journal of psychosomatic research. 2009, Vol 66, Num 3, pp 221-225, issn 0022-3999, 5 p.Article

Selective endothelin_A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue diseaseGIRGIS, Redo E; FROST, Adaani E; TAPSON, Victor F et al.Annals of the rheumatic diseases. 2007, Vol 66, Num 11, pp 1467-1472, issn 0003-4967, 6 p.Article

Pulmonary endothelin-1 clearance in human pulmonary arterial hypertensionLANGLEBEN, David; DUPUIS, J; HIRSCH, A et al.Chest. 2005, Vol 128, Num 6, issn 0012-3692, p. 622S, SUPConference Paper

Effect of chronic infusion of Epoprostenol on echocardiographic right ventricular myocardial performance index and its relation to clinical outcome in patients with primary pulmonary hypertensionSEBBAG, Igal; RUDSKI, Lawrence G; THERRIEN, Judith et al.The American journal of cardiology. 2001, Vol 88, Num 9, pp 1060-1063, issn 0002-9149Article